ArticleJournal of ophthalmology2014
Methotrexate for the treatment of thyroid eye disease.
Article in Journal of ophthalmology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- Periocular methotrexate versus periocular triamcinolone injections for active thyroid-associated orbitopathy: a randomized clinical trial.Japanese journal of ophthalmology · 2023Trial
- Pharmacologic Therapies for Active Moderate-to-Severe TED: A Comprehensive Systematic Review.Clinical medicine insights. Endocrinology and diabetes · 2026Review
- How to manage thyroid eye disease: recent advances - a narrative review.Drugs in context · 2026Review
- Redefining Treatment Paradigms in Thyroid Eye Disease: Current and Future Therapeutic Strategies.Journal of clinical medicine · 2025Review
- The Use of Biologics for Thyroid Eye Disease.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Evaluation of 99Tcm-DTPA orbit SPECT/CT combined with thyroid function test in the treatment of radioactive iodine I-131 in patients with thyroid-associated ophthalmopathy-hyperthyroidism.Journal of medical biochemistry · 2024Article
- A Comprehensive Review of Thyroid Eye Disease Pathogenesis: From Immune Dysregulations to Novel Diagnostic and Therapeutic Approaches.International journal of molecular sciences · 2024Review
- The changing landscape of thyroid eye disease: current clinical advances and future outlook.Eye (London, England) · 2024Review
- Novel perspectives on the pharmacological treatment of thyroid-associated ophthalmopathy.Frontiers in endocrinology · 2024Review
- Role of Peripheral Regulatory T Lymphocytes in Patients with Thyroid Associated Ophthalmopathy During Systemic Glucocorticoid Treatment: A Prospective Observational Study.Current medical science · 2023Observational
- Current concepts regarding Graves' orbitopathy.Journal of internal medicine · 2022Review
- Current Understanding of the Progression and Management of Thyroid Associated Orbitopathy: A Systematic Review.Ophthalmology and therapy · 2020Review
- Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis.Eye (London, England) · 2019Article
- Review
- Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy.American journal of ophthalmology case reports · 2017Article
- Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management.Expert review of ophthalmology · 2017Article
- Methotrexate as a Corticosteroid-Sparing Agent for Thyroid Eye Disease.Journal of clinical & experimental ophthalmology · 2015Article
- Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management.Journal of ophthalmology · 2015Review
- Treatment options for thyroid eye disease.Current treatment options in neurology · 2014Article
- Updates on the understanding and management of thyroid eye disease.Therapeutic advances in ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim. To evaluate the efficacy of methotrexate for the treatment of thyroid eye disease (TED). Methods. 36 consecutive patients with active TED, previously treated with corticosteroids but stopped due to the occurrence of side effects, were commenced on methotrexate therapy. Two different weekly doses were administered depending on the weight of the patient (7.5 mg or 10 mg). Clinical activity score (7-CAS), visual acuity (VA), ocular motility, exophthalmos, and eyelid position were retrospectively evaluated at 3, 6, and 12 months and compared with baseline data. Results. There was a statistically significant improvement in 7-CAS at 3, 6, and 12 months after treatment (P < 0.0001). There was no significant change in visual acuity. Ocular motility disturbances improved at 6 and 12 months (P < 0.001). There was no significant change in exophthalmos (mean 24 mm, SD 3 mm) or eyelid position (marginal reflex distance mean 6 mm, SD 1.5 mm) during the follow-up period. No side effects were registered. Conclusions. Methotrexate therapy is effective in reducing CAS and ocular motility disturbances. No significant improvement in proptosis or eyelid retraction should be expected from this treatment. Eventually, it might be considered a suitable alternative treatment in TED for patients who cannot tolerate steroids.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.